MILPITAS, Calif. -
Jan. 17, 2020 -
PRLog -- Arylamine N-acetyltransferases (NATs, EC 2.3.1.5) are a group of cytosolic, conjugating enzymes involved in phase II xenobiotic metabolism. They transfer an acetyl group from acetyl Coenzyme A to a xenobiotic acceptor substrate. There are two main isoforms, NAT1 and NAT2, which share about 81% amino acid sequence homology. NAT1 is widely expressed in all tissues whereas NAT2 is present primarily, in the liver and intestine. In addition to its role in xenobiotic metabolism, NAT1 plays an important role in folate metabolism. NAT2 is a polymorphic enzyme wherein the slow acetylator phenotype of NAT2 has been linked to urinary bladder cancer whereas the rapid acetylator phenotype has been linked to colorectal cancer. The slow acetylator phenotype has also been widely linked with toxicity due to isoniazid: a widely used tuberculosis drug.
BioVision's Arylamine N-acetyltransferase Activity Assay Kit is a simple, one step plate based assay that measures a fluorescent product. It can measure both NAT1 and NAT2 activity and can detect as low as 1 µU in samples
Figures: (a) Acetylated Standard Curve (b) Enzyme kinetics using Human Liver S9 fraction (160 µg protein/well)
and Rat Liver S9 fraction (120 µg protein/well)
(c) Arylamine N-acetyltransferase specific activity in human and rat liver S9 fractions. Experiments were conducted according to kit K2031 protocol.
For more information on this assay kit, visit
https://www.biovision.com/arylamine-n-acetyltransferase-activity-assay-kit-fluorometric.html
